40,800 volunteers who meet the conditions determined in the Phase 3 study of the domestic inactive Covid-19 vaccine “TURKOVAC”, developed in cooperation with Erciyes University and TÜSEB, will be vaccinated. Volunteers were selected from people between the ages of 18-55, who had not had Covid-19, had not been vaccinated, and did not have chronic diseases related to the immune system.
Developed in cooperation with Erciyes University and the Ministry of Health, Turkish Health Institutes (TÜSEB), one of the 18 ongoing local vaccine studies in Turkey.TURKOVAC“ta do 3 the work phase has begun.
Ministry of Health e-PulseTo date, 846 thousand 451 applications have been received through the “Volunteer for Vaccination Study” button added to . The number of candidate volunteers who met the determined medical criteria was 40,822.
For the Phase 3 study of the local vaccine “TURKOVAC”, the volunteers were between the ages of 18-55, without Covid-19, without positive PCR test, Covid-19 were selected from those who had not been vaccinated and who also did not have a positive chest computed tomography (CT) test or antibody.
In addition, those with Systemic or Cutaneous Lupus Erythematosus, autoimmune diseases, Rheumatoid Arthritis, Guillain-Barre Syndrome, Sjögren’s Syndrome, Glomerulonephritis, Hashimoto’s disease, HIV and giant cell arteritis, which are chronic diseases that affect the immune system, were also excluded from the study.
Candidate volunteers who met the specified conditions also responded to the questionnaire, which included the questions of whether they use public transportation, whether they use public transportation, whether they work, if they work, and whether they work in a public environment, close to people.
In this context, it was found appropriate for 40,800 volunteers from Turkey and abroad, who met the necessary conditions, to participate in the Phase 3 study of the domestic vaccine.
With the development of the first domestic vaccine, Turkey will take its place among the top 10 countries in the world to develop its own vaccine.